Monitoring the efficacy of dendritic cell vaccination by early detection of (99m) Tc-HMPAO-labelled CD4(+) T cells

TY - JOUR

T1 - Monitoring the efficacy of dendritic cell vaccination by early detection of (99m) Tc-HMPAO-labelled CD4(+) T cells

AU - Sharif-Paghaleh, Ehsan

AU - Leech, John

AU - Sunassee, Kavitha

AU - Ali, Niwa

AU - Sagoo, Pervinder

AU - Lechler, Robert I

AU - Smyth, Lesley A

AU - Lombardi, Giovanna

AU - Mullen, Gregory E

PY - 2014/7

Y1 - 2014/7

N2 - Dendritic cell (DC) vaccines have been used to induce tumour-specific cytotoxic T cells [1]. However, this approach to cancer immunotherapy has had limited success. To be successful, injected DCs need to migrate to the lymph nodes (LNs) where they can stimulate effector T cells [1]. We and others have previously demonstrated by magnetic resonance imaging (MRI) that tumour antigen-pulsed-DCs labelled ex vivo with superparamagnetic iron oxide nanoparticles (SPIO) migrated to the draining LNs and are capable of activating antigen-specific T cells [2, 3]. The results from our study demonstrated that ex vivo SPIO-labelled and OVA-pulsed DCs prime cytotoxic CD8(+) T-cell responses to protect against a B16-OVA tumour challenge. In the clinic, a possible non-invasive surrogate marker for efficacy of DC vaccination is to image the specific migration and accumulation of T cells following DC vaccination.

AB - Dendritic cell (DC) vaccines have been used to induce tumour-specific cytotoxic T cells [1]. However, this approach to cancer immunotherapy has had limited success. To be successful, injected DCs need to migrate to the lymph nodes (LNs) where they can stimulate effector T cells [1]. We and others have previously demonstrated by magnetic resonance imaging (MRI) that tumour antigen-pulsed-DCs labelled ex vivo with superparamagnetic iron oxide nanoparticles (SPIO) migrated to the draining LNs and are capable of activating antigen-specific T cells [2, 3]. The results from our study demonstrated that ex vivo SPIO-labelled and OVA-pulsed DCs prime cytotoxic CD8(+) T-cell responses to protect against a B16-OVA tumour challenge. In the clinic, a possible non-invasive surrogate marker for efficacy of DC vaccination is to image the specific migration and accumulation of T cells following DC vaccination.

U2 - 10.1002/eji.201344337

DO - 10.1002/eji.201344337

M3 - Article

C2 - 24643793

SN - 0014-2980

VL - 44

SP - 2188

EP - 2191

JO - European Journal of Immunology

JF - European Journal of Immunology

IS - 7

ER -